Experience of polymyositis and antisynthetase syndrome treatment with rituximab
https://doi.org/10.17650/2222-8721-2012-0-3-45-54
Abstract
The patient with polymyositis and antisynthetase syndrome treated with rituximab (Mabtera) is described. Rituximab was added to the
high‑dose cyclophosphamide therapy due to an acute onset of the disease with a highly progressive interstitial lung disease and inability of the high‑dose corticosteroids therapy because of comorbidity. There was almost complete normalization of pulmonary and muscular pathological changes with more than 4‑fold decrease of anti‑Jo‑1 antibodies on the treatment. No complications and no side effects during rituximab therapy were noted. This case report demonstrates the positive effect of rituximab in combination with high‑dose cyclophosphamide in the treatment of acute AS syndrome. The results published in literature are discussed.
About the Authors
S. G. Palshina
Research Institute of Rheumatology of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
S. S. Nikitin
The Institute of General Pathology and Pathophysiology of Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. I. Vasilyev
Research Institute of Rheumatology of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
References
1. Антелава О.А. Идиопатические воспалительные миопатии. Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР‑Медиа, 2008. С. 502−17.
2. Антелава О.А., Тарасова Г.М., Сажина Е.Г. и др. Антисинтетазный синдром — наиболее тяжелый подтип полимиозита/дерматомиозита (описание случаев). Совр ревматол 2009; 4:54−8.
3. Solomon J., Swigris J.J., Brown K.K. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 2011;37:100−9.
4. Katzap E., Barilla‑LaBarca M.L., Marder G. Antisynthetase syndrome. Curr Rheumatol. Rep., 2011;13:175−81.
5. Антелава О.А., Олюнин Ю.А., Балабанова Р.М. и др. Особенности дебюта и течения антисинтетазного синдрома как наиболее тяжелого подтипа полимиозита/дерматомиозита. РМЖ 2009;21:1443.
6. Labirua A., Lundberg I.E. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 2010;22:633−8.
7. Marie I., Hachulla E., Hatron P.Y. et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001; 28:2230−7.
8. Gottenberg J.E., Guillevin L., Lambotte O. et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis 2005;64: 913−20.
9. Lambotte O., Kotb R., Maigne G. et al. Efficacy of rituximab in refractory polymyositis. J. Rheumatol 2005; 32:1369−70.
10. Brulhart L., Waldburger J.M., Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006;65:974−5.
11. Берлит П. Неврология. Справочник. Пер. с нем. Под ред. А.Ю. Емельянова. М.: МЕДпресс‑информ, 2010. С. 466−71.
12. Vandenbroucke E., Grutters J.C., Altenburg J. et al. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009;29:1499−502.
13. Frikha F., Rigolet A., Behin A. et al. Efficacy of rituximab in refractory and relapsing myositis with anti‑JO1 antibodies: a report of two cases. Rheumatol (Oxford) 2009;48:1166−8.
14. Sem M., Molberg O., Lund M.B. et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatol (Oxford) 2009;48:968−71.
15. Ball E.M.A., Savage E.M., Pendleton A. Refractory anti-synthetase syndrome treated with rituximab. Rheumatol (Oxford) 2010; 49:1013.
16. Marie I., Dominique S., Janvresse A. et al. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 2012;106:581−7.
17. Limaye V., Hissaria P., Liew C.L. et al. Efficacy of rituximab in refractory antisynthetase syndrome. Intern Med J 2012;42:4−7.
18. Kulkarni H.S., Aggarwal R. Successful treatment of acute respiratory failure using rituximab and cyclophosphamide as a combination immunosuppressive regimen in a ventilator-dependent patient having antisynthetase syndrome. Am J Respir Crit Care Med 2011;183;A5661.
19. Антелава О.А., Насонов Е.Л. Ритуксимаб в лечении идиопатических воспалительных миопатий. Анти‑В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. Е.Л. Насонова. М.: ИМА‑ПРЕСС, 2012. С. 178−89.
20. Krystufková O., Vallerskog T., Helmers S.B. et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies [abstract]. Ann. Rheum Dis 2009;68:836−43.
21. Engel P., Gómez‑Puerta J.A., Ramos‑Casals M. et al. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011;63:127−56.
22. Насонов Е.Л., Каратеев А.Е., Клюквина Н.Г. Базисные противовоспалительные препараты (в том числе цитотоксические препараты). Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М., ГЭОТАР‑Медиа, 2008, 219−222.
23. Tsiveriotis K., Tsirogianni A., Pipi E. et al. Antineutrophil cytoplasmic antibodies testing in a large cohort of unselected Greek patients. Autoimmune Dis 2011;626495,9. (опубликовано онлайн 3 мая 2011).
24. Haghighi A., Forghanizadeh J., Bagher Owlia M. et al. Antineutrophil cytoplasmic antibody (ANCA) in connective tissue diseases. J Indian Acad Clin Medic 2005;6:216−9.
25. Schönermarck U., Lamprecht P., Csernok E. et al. Prevalence and spectrum of rheumatic diseases associated with proteinase 3‑antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase- ANCA. Rheumatol (Oxford);2001; 40:178−84.
Review
For citations:
Palshina S.G., Nikitin S.S., Vasilyev V.I. Experience of polymyositis and antisynthetase syndrome treatment with rituximab. Neuromuscular Diseases. 2012;(3):45-54. (In Russ.) https://doi.org/10.17650/2222-8721-2012-0-3-45-54
Views:
1544
Email this article 